Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia by McGahan , L
 Horizon Scanning 
in Oncology 
Ibrutinib (Imbruvica®) in 
combination with rituximab 
for the treatment of 
Waldenström’s 
macroglobulinemia 
 
 
 
DSD: Horizon Scanning in Oncology No. 85 
ISSN online 2076-5940 
 Horizon Scanning 
in Oncology 
Ibrutinib (Imbruvica®) in 
combination with rituximab 
for the treatment of 
Waldenström’s 
macroglobulinemia 
 
 
Vienna, November 2018 
 Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft 
 
Authors:  Lynda McGahan, MSc 
Internal review: Priv.-Doz. Dr. phil. Claudia Wild; Nicole Grössmann, MSc 
External review: Prof. Dr. med. Christian Buske 
 Universitätsklinikum Ulm, Institut für Experimentelle Tumorforschung 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited literature search.  
It is not a definitive statement on safety, effectiveness or efficacy and cannot replace professional medical advice nor 
should it be used for commercial purposes. 
The HTA Core Model® for Rapid Relative Effectiveness for Pharmaceuticals, developed within EUnetHTA 
(www.eunethta.eu), has been utilised when producing the contents and/or structure of this work. A working version 
(unpublished) of V3.0 of the Model was used. Use of the HTA Core Model® does not guarantee the accuracy, 
completeness, quality or usefulness of any information or service produced or provided by using the Model 
 
 
 
 
CONTACT INFORMATION 
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)  
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicise  
the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
http://eprints.hta.lbg.ac.at 
DSD: Horizon Scanning in Oncology No. 85 
ISSN-online: 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2018 LBI-HTA – All rights reserved 
Ibrutinib plus rituximab for the treatment of Waldenström’s macroglobulinemia 
LBI-HTA | 2018 3 
Abstract 
Introduction 
Constitutive Bruton tyrosine kinase (BTK) activation is associated with B-
cell proliferation and lymphoma progression. In patients with Walden-
ström’s macroglobulinemia (WM), a highly prevalent somatic mutation in 
the Myeloid Differentiation 88 signalling adaptor (MYD88 L265P) poten-
tiates cell survival through BTK activation of nuclear factor kappa B 
(NFB). Ibrutinib, a first-generation BTK inhibitor, selectively and irrevers-
ibly binds BTK, blocking B-cell receptor signaling and inducing apoptosis 
in WM cells harboring the MYD88 mutation. 
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials.  
Results of the iNNOVATE trial 
In the phase III, iNNOVATE trial, 150 symptomatic treatment naïve or re-
lapsed/refractory WM patients were randomised 1:1 to 420 mg oral ibrutinib 
or placebo daily, in combination with 375 mg/m
2
 rituximab IV once weekly 
for four weeks, followed by another four-week course after a three-month in-
terval. Adding ibrutinib prolonged progression-free survival (PFS) by 54%, 
conferring a longer PFS than rituximab alone (not reached versus 20.3 
months, respectively) and reducing the relative risk of progression or death 
by 80%. The PFS benefit was observed regardless of previous treatment, 
MYD88 or C-X-C chemokine receptor type 4 (CXCR4) genotype, or prog-
nostic score. At 30 months, the overall survival (OS) rates were 94% versus 
92% for ibrutinib- and placebo combination, respectively, with permitted 
crossover for patients in the placebo arm to ibrutinib single in the case of 
progression; median OS was not reached in either group. Adding ibrutinib 
increased the overall response rate (ORR) by 45% compared with rituximab 
alone, largely independent of the genotype. Adding ibrutinib to rituximab 
therapy increased the number of patients with sustained haemoglobin (Hb) 
by 32% and resulted in fewer immunoglobulin M (IgM) flares (8% versus 
47%, respectively). Atrial fibrillation and bleeding events were 12% and 30% 
more common in patients receiving ibrutinib combination versus rituximab 
alone, respectively.  
Conclusion 
Overall, adding ibrutinib to rituximab therapy increases PFS and ORR, and 
reduces the risk of death and progression for symptomatic WM patients with 
untreated or recurrent disease. Consistent PFS and OR benefit were ob-
served regardless of line, genotype or prognostic score. Further evaluation is 
needed to identify the role of ibrutinib as first-line versus salvage therapy; 
monotherapy versus in combination with biologic agents, other small mole-
cules or chemoimmunotherapy; optimal duration of treatment; management 
of ibrutinib intolerant or resistant patients; and the comparative safety and 
effectiveness with new BTK inhibitors.  
Horizon Scanning in Oncology 
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is ibrutinib? 
A0022 Who manufactures ibrutinib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ibrutinib received marketing authorisation? 
Health problem and current use 
A0002 What is Waldenström’s macroglobulinemia? 
A0004 What is the natural course of Waldenström’s macroglobulinemia? 
A0006 What are the consequences of Waldenström’s macroglobulinemia for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of disease or health condition? 
A0003 What are the known risk factors for Waldenström’s macroglobulinemia? 
A0024 
How is Waldenström’s macroglobulinemia currently diagnosed according to published 
guidelines and in practice? 
A0025 
How is Waldenström’s macroglobulinemia currently managed according to published 
guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ibrutinib on mortality? 
D0005 
How does ibrutinib affect symptoms and findings (severity, frequency) of Waldenström’s 
macroglobulinemia? 
D0006 
How does ibrutinib affect progression (or recurrence) of Waldenström’s 
macroglobulinemia? 
D0011 What is the effect of ibrutinib on patients ̕ body functions? 
D0012 What is the effect of ibrutinib on generic health-related quality of life? 
D0013 What is the effect of ibrutinib on disease-specific quality of life? 
Safety 
C0008 How safe is ibrutinib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ibrutinib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of ibrutinib? 
A0021 What is the reimbursement status of ibrutinib? 
 
EUnetHTA 
HTA Core Model® 
Horizon Scanning in Oncology 
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2 Drug description 
Generic/Brand name/ATC code:  
Ibrutinib/Imbruvica
®
/L01xE27/PCI-32765 
 
B0001: What is ibrutinib? 
Constitutive Bruton tyrosine kinase (BTK) activation is associated with B-
cell proliferation and the progression of B-cell lymphomas. In patients with 
Waldenström’s macroglobulinemia (WM), a highly prevalent somatic mu-
tation in WM MYD88 L265P potentiates cell survival through BTK activa-
tion of nuclear factor kappa B (NFB) [2]. Ibrutinib, a first-generation 
BTK inhibitor, selectively and irreversibly binds BTK, blocking B-cell re-
ceptor signalling and inducing apoptosis in WM cells harbouring the 
MYD88 mutation [3].  
Ibrutinib is available in 90- and 120-capsule bottles of 140 mg capsules. It is 
administered as three 140 mg oral capsules, taken with eight ounces of water 
once daily, until disease progression or unacceptable toxicity [4]. Patients 
also receive 375 mg/m
2
 rituximab by intravenous (IV) infusion once weekly 
for four weeks, followed by another four-week rituximab course after a three-
month interval [5]. 
Prior to initiating ibrutinib, patients undergo baseline renal and hepatic 
function tests, and coagulation status. Those with cardiac risk factors, a his-
tory of atrial fibrillation, or acute infections require a baseline electrocardio-
gram (ECG) prior to starting ibrutinib. Patients receiving ibrutinib undergo 
monthly complete blood counts (CBC) and monitoring for symptoms of 
atrial fibrillation, infection, hepatitis B reactivation, fever, tumour lysis syn-
drome, and hypertension. Serum creatinine levels are monitored periodical-
ly in patients with renal impairment. Due to the risk for increased bleeding, 
ibrutinib is not for use in patients with moderate or severe hepatic impair-
ment; a dose reduction to 140 mg may be considered in patients with mild 
hepatic impairment. Patients should avoid concomitant use of strong 
CYP3A inhibitors or inducers, grapefruit or Seville oranges, anticoagulants 
or platelet inhibitors, or medications that prolong the QT interval [4].  
 
A0022: Who manufactures ibrutinib? 
Janssen Inc and Pharmacyclics LLC (an AbbVie company) 
 
 
 
 
 
first-generation BTK 
inhibitor 
420 mg oral ibrutinib 
once/day + two 4-week 
courses of rituximab 
(375 mg/m2 IV) 
monitor CBC, ECG, renal 
and hepatic function; 
reduce/interrupt 
dose/discontinue for 
safety/tolerability 
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3 Indication 
A0007: What is the target population in this assessment? 
Ibrutinib (Imbruvica
®
) is indicated, in combination with rituximab, for pre-
viously untreated Waldenström’s macroglobulinemia (WM) and for those 
with rituximab-sensitive disease recurrence.  
 
 
 
4 Current regulatory status 
A0020: For which indications has ibrutinib received marketing authorisa-
tion? 
In January 2015, the US Food and Drug Administration (FDA) approved ib-
rutinib monotherapy for the treatment of relapsed or refractory WM 
through the Breakthrough Therapy Designation Pathway. Approval was 
based on the overall response rate (ORR) reported in a phase II multicentre 
study [6]. In August 2018, the approval was expanded to include combina-
tion use with rituximab across all lines of therapy for WM. This chemother-
apy-free combination for WM was approved based on 30-month progression-
free survival (PFS) rates reported in the herein-assessed phase III iNNO-
VATE trial [7, 8]. 
Ibrutinib was granted its first approval by the FDA in November 2013 for 
the treatment of relapsed or refractory mantle cell lymphoma (MCL). The 
accelerated approval was based on ORR and PFS data reported in a phase II 
study [9, 10]. From 2014 to 2016, the FDA expanded approval for use in 
previously-treated chronic lymphocytic leukaemia (CLL) for patients with 
or without a genetic mutation in chromosome 17 (del 17p), and as first-line 
therapy. The indication was further expanded, in May 2016, to include pa-
tients with small lymphocytic lymphoma (SLL). In 2017, ibrutinib under-
went accelerated approval for relapsed or refractory marginal zone lympho-
ma (MZL) in patients requiring systemic therapy after anti-CD20-based 
therapy, and expanded approval for previously-treated chronic graft versus 
host disease (cGVHD) [4].  
Ibrutinib received orphan medicine status by the European Medical Agency 
(EMA) in 2012 for the treatment of CLL, and is approved as second-line 
therapy for MCL, any-line monotherapy for CLL, and in combination with 
bendamustine and rituximab for previously-treated CLL. Ibrutinib was 
granted orphan designation for the treatment of MZL in August 2015 and 
GVHD in 2016 [11, 12]. In July 2015, ibrutinib received European Commis-
sion (EC) approval as monotherapy for relapsed and refractory WM, or as 
first-line therapy for patients unsuitable for immunochemotherapy [13, 14]. 
There is currently no indication as to when the EMA may receive a market-
ing authorisation application (MAA) to extend the use of ibrutinib in com-
bination with rituximab for WM based on results of the iNNOVATE trial.  
 
previously untreated 
and rituximab-sensitive 
recurrent WM 
FDA approvals:  
 
monotherapy for pre-
treated WM in 2015; 
in combination with 
rituximab for WM in 
August 2018 
relapsed/refractory 
MCL, any-line CCL, SLL, 
pre-treated MZL 
requiring systemic 
therapy after anti-CD20-
based therapy;  
pre-treated cGVHD 
EMA approvals:  
 
2nd-line MCL, any-line 
for CCL, in combination 
with bendamustine and 
rituximab for pre-
treated CLL, MZL, GVH;  
monotherapy for pre-
treated WM or 1st- line 
for those unsuitable for 
immunochemotherapy 
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5 Burden of disease 
A0002: What is Waldenström’s macroglobulinemia? 
WM or lymphoplasmacytic lymphoma, is an indolent B-cell non-Hodgkin 
lymphoma (NHL) affecting lymphoplasmacytoid and plasma B-cells. It is 
characterised by an accumulation of malignant B-cells in the bone marrow 
(BM) and an overproduction of abnormal monoclonal protein immuno-
globulin (Ig) M or macroglobulin in the blood [15]. Approximately 91% of 
WM patients have a leucine to proline somatic mutation (MYD88 L265P) 
in the Myeloid Differentiation 88 signalling adaptor (MYD88) [6]. Somat-
ic mutations reminiscent of Warts, Hypogammaglobulinemia, Infections, 
and Myelokathesis (WHIM) in the C-X-C chemokine receptor type four 
have been observed in 27–40% of WM patients. These mutations may be 
nonsense (CXCR4 WHIM/NS) or frameshift (CXC44 WHIM/FS) muta-
tions resulting in the formation of a truncated receptor protein. In tumour 
cells, MYD88 L265P constitutively activates NF-B through two distinct 
pathways involving BTK and the interleukin-1 receptor-associated kinases 
(IRAK1 and IRAK4) to potentiate cell survival [16]. 
The MYD88 L265P with CXCR4 WHIM/FS genotype is associated with se-
vere disease, greater BM involvement, and increased likelihood of develop-
ing viscosity-related complications with higher serum IgM levels compared 
to those of MYD88 L265P/CXCR4 WHIM/NS genotype. Patients with 
MYD88 Wild Type (WT)/CXCR4 WT have the lowest BM involvement. 
Despite the association of severe disease with MYD88 L265P/CXCR4 
WHIM/NS or FS mutations compared to MYD88 WT/CXCR4 WT, survival 
outcomes do not appear to be affected by the presence of CXCR4 mutations. 
Better outcomes are observed in patients with MYD88 L265P genotype 
compared to those with MYD88 WT genotype, and the risk of death is ten-
fold less. The presence of MYD88 and CXCR4 mutations affects responsive-
ness to ibrutinib. [17, 18].  
 
A0004: What is the natural course of Waldenström’s macroglobulinemia? 
Approximately 25% of WM patients are asymptomatic at diagnosis and are 
considered to have smouldering WM (SWM). Patients with IgM protein 
<3 g/dL are considered to have IgM monoclonal gammopathy of unde-
termined significance (IgM-MGUS). As malignant B-cells grow mainly in 
the BM, they disrupt normal haematopoiesis of erythrocytes, white cells 
and platelets. Low levels of red blood cells result in anaemia and fatigue, 
low white blood cells increase the risk of infection, and low platelets cause 
increased bleeding and bruising. While active WM typically involves the 
BM, it progresses over time causing abnormal blood cells, known as B lym-
phocytes, to grow within the lymph nodes, liver, spleen, stomach, intestines 
or lungs. While rare, WM may progress to multiple myeloma [15, 16].  
 
 
 
 
WM: B-cell non-
Hodgkin lymphoma; BM 
infiltration, increased 
IgM 
 
 
MYD88 L265P and 
WHIM-like CXCR4 
mutations in 91% and 
27-40% of WM 
patients, resp. 
MYD88 L265P and 
CXCR4 WHIM/NS or FS: 
severe disease 
 
MYD88 L265P:  
better outcomes 
malignant B-cells 
infiltrate BM, disrupt 
haematopoiesis; 
metastasize to lymph 
nodes, liver, spleen, 
stomach, intestines, 
lungs 
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A0006: What are the consequences of Waldenström’s macroglobulinemia for 
the society? 
The overall survival (OS) rate of smoldering WM approximates that of the 
average age-matched population [19]. During a 15-year follow-up study, the 
rate of progression of smoldering WM to symptomatic WM was 71% and the 
cumulative risk of progression of smoldering WM to symptomatic WM, am-
yloidosis, or a related disorder was 6% at one year, 39% at three years, 59% 
at five years, and 68% at ten years [20]. The overall relative five-year survival 
of those with WM is approximately 78%. Median survival rates for patients 
of low-, intermediate-, and high-risk according to the International Prognos-
tic Scoring System for WM (IPSSWM) are 12, 8, and 3.5 years, respectively 
[21, 22].  
 
A0023: How many people belong to the target population? 
WM represents approximately 1–3% of all NHLs. Of the 1,318 new cases 
of NHLs diagnosed in 2015, approximately 26 are due to WM [23]. Ac-
cording to the European WM network, five in 1,000,000 people per year 
are diagnosed with WM [24]. The incidence rate is higher in men than 
women, 3.4 versus 1.7 per million, respectively, with a median age of diag-
nosis of between 63 and 68 years [15, 25]. Incidence is higher among Amer-
icans of European descent, while African American descendants represent 
approximately 5% of all patients [18].  
 
A0005: What are the symptoms and the burden of disease or health condi-
tion? 
Patients with WM exhibit symptoms related to increased serum IgM and/or 
BM lymphoplasmacytic infiltration. B symptoms include recurrent fever, 
night sweats, and weight loss. Fatigue is associated with anaemia (haemo-
globin [Hb] ≤10 g/dL), bleeding results from thrombocytopenia (<100 
g/L), and infections may occur due to low white blood cells. An overproduc-
tion of serum macroglobulin can cause peripheral neuropathy, impaired 
kidney function, and systemic amyloidosis with organ damage. A large ac-
cumulation of IgM proteins (>50 g/L) in the blood causes hyperviscosity 
syndrome in 10–30% of WM patients. Associated symptoms include bleed-
ing from the nose, gums or lining of the gastrointestinal tract, headache, ver-
tigo, blurred vision, altered mental status and shortness of breath. Sympto-
matic hyperviscosity syndrome requires plasmapharesis. Approximately 
10% of WM patients have acquired haemolytic anaemia where red blood 
cells are destroyed by macroglobulin when a patient encounters a low tem-
perature environment. Up to 20% of WM patients develop cryoglobulinemia 
where macroglobulin in the blood becomes thick when exposed to cold tem-
peratures causing circulatory problems [15].  
 
 
 
 
 
IPSSWM risk-stratified 
median OS: 
 
low: 12 years 
intermediate: 8 years 
high: 3.5 years 
WM:  
5 in 1,000,000 
people/year 
 
incidence: higher in 
older Caucasian males of 
European descent 
WM symptoms:  
 
fever, night sweats, 
weight loss, fatigue, 
bleeding, infection, 
neuropathy,  
impaired kidney 
function,  
systemic amyloidosis 
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A0003: What are the known risk factors for Waldenström’s macroglobu-
linemia? 
WM is staged based on the patient’s risk status using the IPSSWM. Overall, 
five adverse covariates have been identified, including age >65 years, Hb 
≥11.5 g/dL, platelet count ≤100,000/mm3, ß2-microglobulin level >3 mg/L, 
and serum IgM level >7.0 g/dL. Patients at low risk are less than 65 years of 
age with fewer than two adverse covariates. Patients at intermediate risk are 
over 65 years of age and have two adverse covariates [15]. High-risk patients 
have two or more adverse covariates. First-degree relatives of WM patients 
have a 20-fold increased risk of developing WM, and a three- to five-fold 
increased risk of developing another NHL, CLL, or IgM-MGUS [26]. Peo-
ple with chronic hepatitis C infection or autoimmune diseases may also be 
at increased risk for WM [21].  
 
A0024: How is Waldenström’s macroglobulinemia currently diagnosed ac-
cording to published guidelines and in practice? 
According to The Second International Workshop on WM (IWWM), active 
WM is diagnosed based on the detection of BM lymphoplasmacytic infiltra-
tion and serum IgM monoclonal protein identified through BM biopsy and 
immunophenotyping [27]. The typical immunophenotypic profile of the in-
filtrate is surface IgM+, CD5±, CD10-, CD19+, CD20+, CD22+, CD23-, 
CD25+, CD27+, FMC7+, CD103-, and CD138+ [16]. Whole genome or 
paired tumour/normal sequencing is used to detect the highly recurrent 
MYD88 L265P mutation and frameshift or nonsense CXCR4 mutations pre-
sent in approximately 91% and 27–40% of WM patients, respectively. Tu-
mour burden and treatment response are evaluated by performing serum 
immunoelectrophoresis, immunoglobulin measurement, CT scans involving 
pelvis, abdomen, chest and cervical area, cold agglutin, and cryoglobulins 
measurements [27, 28]. 
 
 
 
6 Current treatment 
A0025: How is Waldenström’s macroglobulinemia currently managed ac-
cording to published guidelines and in practice? 
Approximately 25% of WM patients are asymptomatic at diagnosis; those 
with IgM-GUS or SWM with preserved marrow function undergo surveil-
lance. According to the Second IWWM, therapy is indicated when patients 
report WM-related constitutional symptoms [15]. Currently, there is no sin-
gle or combination standard treatment used for all patients. WM patients 
may be treated with alkylating and other chemotherapy agents, purine nu-
cleoside analogues, monoclonal antibodies, corticosteroids, immunomodula-
tory agents and proteasome inhibitors used as monotherapy or in combina-
tion. Treatment per IPSSWM risk-stratification involves the following op-
tions [15, 27, 28]: 
IPSSWM:  
risk based on 5 adverse 
covariates —age, Hb, 
platelet count, ß2-
microglobulin, and 
serum IgM  
diagnosis:  
 
BM biopsy and 
immunophenotyping 
 
genotyping for  
MYD88 L265P and 
CXCR4 mutations 
surveillance: 
 IgM-GUS and SWM 
treatment per IPSSWM 
risk-stratification 
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 Newly diagnosed patients with hyperviscosity require therapeutic 
plasma exchange prior to cytoreductive therapy. 
 Rituximab is indicated for untreated WM with symptomatic mild to 
moderate anaemia, symptomatic cryoglobulinemia (in combination 
with steroids), or haemolytic anaemia unresponsive to corticosteroids.  
 First-line therapy for WM involves 4–6 cycles of bendamustine and 
rituximab.  
 Carfilzomib-based regimens offer a neuropathy-sparing option for 
untreated WM patients. 
 Dexamethasone-rituximab-cyclophosphamide (DRC) or oral fludar-
abine for treatment-naïve elderly patients when the disease burden is 
low. 
 A bortezomib-based combination (bortezomib-rituximab-
dexamethasone) for patients with high IgM levels, symptomatic hy-
perviscosity, cryoglobulinemia or cold agglutinemia, amyloidosis, and 
renal impairment provided the patients’ underlying peripheral neu-
ropathy is of grade ≤2. 
 Ibrutinib monotherapy for treatment-naïve patients that are not suit-
able for chemoimmunotherapy, those with a MYD88 mutation irre-
spective of the presence of CXC4 mutation, and for relapsing WM. 
 Previously-treated WM patients that are intolerant to rituximab may 
benefit from ofatumumab. 
 Everolimus or purine analogues are suitable in selected patients with 
refractory or multiply relapsed disease.  
 Relapsing patients may repeat a previous therapy if they achieved 
durable remission without toxicity to prior therapy.  
 Autologous stem cell transplantation (ASCT) should be considered 
for first or second relapse in transplant-eligible patients with chemo-
sensitive disease.  
 
 
 
7 Evidence 
A literature search was conducted on 11 October 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “ibrutinib”, “imbruvica”, “Waldenstroms Macroglobu-
linemia”, “Waldenstrom Macroglobulinemia”, “lymphoplasmacytic lym-
phoma” and “rituximab”. The manufacturer was also contacted and submit-
ted a reference that had already been identified by systematic literature 
search [7], along with an accompanying oral presentation [29]. A manual 
search identified five statistical reports [17, 20, 21, 25, 26], two FDA approv-
al documents [4, 8], three EMA marketing authorization documents [11, 12, 
14], four clinical guidance documents [6, 15, 19, 24], four clinical trial arti-
cles [5, 9, 10, 30], and two cost documents [23, 31].  
Overall, 122 references were identified. Included in this reported are:  
 iNNOVATE, phase III [5, 7, 29, 30] 
1st-line:  
 
rituximab monotherapy, 
DRC, bortezomib- or 
carfilzomib-based 
regimens, 
bendamustine-
rituximab, ibrutinib, and 
plasmapheresis 
 
 
 
 
 
 
 
 
 
 
2nd-line:  
 
ofatumumab, 
nucleoside analogues, 
ibrutinib, everolimus, 
immunomodulatory 
agents, and ASCT 
systematic literature 
search in 5 databases:  
103 hits 
 
 
manual search: 
 20 additional references 
 
overall: 123 references 
included: 2 studies 
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 Ibrutinib in previously treated WM, phase II study [6] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [32]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effective-
ness assessment of pharmaceuticals, considering the following elements: 
population, intervention, comparator, outcomes and setting [33]. 
The evaluation of the magnitude of “clinically meaningful benefit” that can 
be expected from a new anti-cancer treatment, the Magnitude of Clinical 
Benefit Scale developed by the European Society for Medical Oncology 
(ESMO-MCBS) was not applied, since it can only be used for the evaluation 
of solid tumour drugs [34]. 
 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
 
 
 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
external validity 
ESMO-MCBS could not 
be assessed 
internal and external 
review  
 
quality assurance 
method 
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7.2 Clinical efficacy and safety –  
phase III studies 
iNNOVATE (NCT02165397) is a multicentre, double-blind, randomised, in-
terventional phase III trial involving 150 patients with symptomatic un-
treated WM or disease recurrence [7]. The study was designed to evaluate 
whether adding ibrutinib to rituximab prolongs PFS and ORR in WM pa-
tients compared to rituximab alone. Efficacy analyses were based on all ran-
domly assigned patients comprising the intent-to-treat (ITT) population. 
Safety analyses involved all patients who received at least one dose of the 
study drug; all randomly assigned patients received at least one dose of ibru-
tinib or placebo in combination with rituximab.  
Eligible patients were 18 years or older, with centrally confirmed sympto-
matic untreated or previously treated WM, with an Eastern Cooperative On-
cology Group (ECOG) performance status ≤2. Patients were excluded if 
they had known central nervous system (CNS) involvement, bleeding disor-
ders, active systemic infection or cardiovascular disease, history of stroke or 
intracranial haemorrhage, prior BTK therapy, hypersensitivity or resistance 
to rituximab-containing therapy, or received rituximab within twelve 
months of study entry. Study participants were stratified according to 
IPSSWM score at screening (low versus intermediate versus high), number 
of prior regimens (0 versus 1 or 2 versus ≥3), and ECOG performance-status 
(0 or 1 versus 2; range from 0 to 5).  
Patients were randomised 1:1 to 420 mg of oral ibrutinib or placebo until 
disease progression or toxicity. Patients also received 375 mg/m
2
 rituximab 
IV once weekly for four weeks, followed by another four-week rituximab 
course after a three-month interval [5]. Patients on placebo were allowed to 
cross over to receive ibrutinib after disease progression as confirmed by the 
blinded independent review committee (BICR). Dose reductions or inter-
ruptions were allowed for any potentially study drug-related event and dis-
continued if toxicities persist or recur following two dose reductions. The 
median duration of treatment (DOT) was 25.8 months (range 1.0 to 37.2 
months) for patients receiving ibrutinib combination and 15.5 months 
(range 0.4 to 34.3) for those receiving placebo combination. 
At data cut-off, 50 events of disease progression or death had occurred. In 
the ITT population, 75% (56/75) of ibrutinib combination and 35% (26/75) 
of placebo combination patients were still receiving the assigned treatment. 
In the placebo combination group, 40% (30/75) crossed over to ibrutinib fol-
lowing BIRC-assessed (blinded independent review committee-assessed) 
disease progression during the trial and three (4%) patients received ibru-
tinib outside of the trial. During a median follow-up of 26.5 months, four 
deaths occurred in the ibrutinib combination group and six occurred in the 
placebo combination group.  
iNNOVATE: ibrutinib + 
rituximab versus 
placebo + rituximab for 
symptomatic untreated 
WM or disease 
recurrence 
ITT (n = 150):  
stratified by IPSSWM 
score, number of prior 
regimens, and ECOG 
performance status 
420 mg ibrutinib + 
rituximab versus placebo + 
rituximab 
 
median DOT:  
25.8  months for ibrutinib 
combination versus  
15.5 months for placebo 
combination 
 
death/progression at 
data cut-off: 50 events 
 
40% cross-over to 
ibrutinib 
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The primary endpoint was PFS, as assessed by the BIRC, based on the modi-
fied Consensus Response Criteria from the VI
th 
International Workshop for 
WM, National Cancer Care Network. Secondary endpoints included BICR-
assessed ORR; time to next treatment (TTNT); rate of sustained Hb im-
provement; proportion of patients with ≥3 point increase from baseline by 
week 25 in the Functional Assessment of Chronic Illness Therapy (FACIT)–
Fatigue subscale score; OS and safety. Exploratory endpoints included in-
vestigator-assessed PFS and ORR, duration of response (DOR); clinical re-
sponse rate (CRR, ≥minor response [MR]); IgM, HgB, lymph nodes and 
spleen measures, tumour involvement of BM, EQ-5D-5L visual analogue 
scale and utility score, Functional Assessment of Cancer Therapy–Anaemia 
(FACT-An) total score and subscale scores. During treatment, endpoints 
were assessed every four weeks for 16 weeks, and every eight weeks thereaf-
ter until disease progression. The mutational status of MYD88 and CXCR4 
were assessed from BM samples obtained from patients prior to starting 
therapy. AEs were graded for severity according to the National Cancer In-
stitute Common Terminology Criteria (CTCAE) version 4.03.  
The ITT population (n = 150) had a median age of 69 years (range 36–89), 
66% were male, 79% had extra-medullary disease, 80% had an intermediate 
or high prognostic score, and 45% were treatment-naïve. Patients with re-
lapsed disease had received a median of two prior therapies (range 1–6); of 
these, 85% were previously treated with rituximab. Of the 136 patients for 
whom baseline mutational data were available, MYD88 L265P and CXCR4 
WHIM genotypes were found in 85% and 36%, respectively. Detailed pa-
tient characteristics including inclusion- and exclusion criteria can be found 
in Table 4 and study quality is described in Table 5 of the appendix, respec-
tively. Clinical efficacy data are presented in   
primary endpoint:  
BICR-assessed PFS 
 
secondary endpoints: 
ORR, TTNT,  
Hb improvement, OS, 
FACIT-fatigue and 
safety 
 
exploratory endpoints: 
investigator-assessed 
PFS and ORR, DOR, 
CRR, IgM, HgB 
ITT: median age 69 
years, 80%  
intermediate/high 
prognostic score; 85% 
previously received 
rituximab  
 
genotypes:  
MYD88 L265: 85% 
CXCR4 WHIM: 36% 
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Table 1 and AEs are listed in Table 2. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of ibrutinib on mortality? 
The secondary endpoint of BICR-assessed median OS was not reached in ei-
ther group. At a median follow-up of 26.5 months, four deaths had occurred 
in the ibrutinib combination group during long-term follow-up and six had 
occurred in the placebo combination group during treatment. The 30-month 
OS rate was 94% for ibrutinib combination versus 92% for placebo combina-
tion. Following BICR-assessed disease progression, 30 placebo combination 
patients crossed over to receive ibrutinib and three patients received ibru-
tinib outside of the trial. 
 
D0006: How does ibrutinib affect progression (or recurrence) of Walden-
ström’s macroglobulinemia? 
At 30 months, the primary endpoint, rate of PFS was 82% in the ibrutinib 
combination group and 28% in the placebo combination group (median, not 
reached versus 20.3 months; hazard ratio [HR] for progression or death 0.20, 
95% confidence interval [CI] 0.11–0.38; p < 0.001). Investigator-assessed 
PFS was similar (HR 0.22, 95% CI 0.12–0.40; p < 0.001). 
The PFS benefit of ibrutinib combination over placebo combination was 
demonstrated across predefined subgroups in both untreated WM and re-
lapsed disease (n = 68 treatment naïve, HR 0.34, 95% CI 0.12–0.95; p < 
0.001; n = 82 relapsed disease, HR 0.17, 95% CI 0.08–0.36; p < 0.001). At 24 
months, the PFS rate among treatment naïve patients was 84% in the ibru-
tinib combination group and 59% in the placebo combination group. Since 
untreated WM patients were enrolled following a protocol amendment, 30-
month PFS rates could not be estimated. In patients with disease recurrence, 
the 24-month PFS rate was 80% in the ibrutinib combination group and 
37% in the placebo combination group; and 80% and 22%, respectively at 30 
months.  
The PFS benefit of ibrutinib combination over placebo combination was al-
so consistent across different MYD88 and CXCR4 genotypes and IPSSWM 
prognostic scores. At 30 months, PFS rates were 86% versus 33% among pa-
tients with the MYD88 L265P/CXCR4 WT genotype, 80% versus 29% 
among those with the MYD88 L265P/CXCR4 WHIM genotype, and 80% 
versus 21% among those with the MYD88 WT/CXCR4 WT genotype (n = 
67 MYD88 L265P/CXCR4 WT, HR 0.17, 95% CI 0.06–0.49; p < 0.001; n = 
49 MYD88 L265P/CXCR4 WHIM, HR 0.24, 95% CI 0.09–0.66; p < 0.001; n 
= 20 MYD88 WT/CXCR4 WT, HR 0.21, 95% CI 0.04–1.08; p < 0.001). The 
30-month PFS rates were 93% versus 22%, 70% versus 28%, and 86% versus 
42% for patients of high, intermediate, and low prognostic scores, respec-
tively (n = 32 low, HR 0.16, 95% CI 0.03–0.76; p < 0.001; n = 61 intermedi-
ate, HR 0.43, 95% CI 0.19–1.00; p < 0.001; n =57 high, HR 0.07, 95% CI 
0.02–0.31; p < 0.001).  
 
median OS: not reached 
in either group 
 
30 month OS rate:  
ibrutinib + rituximab: 
94%  
placebo + rituximab: 
92%  
30-month PFS rate: 
ibrutinib + rituximab: 
82% 
placebo + rituximab: 
28% 
consistent PFS benefit 
across subgroups 
regardless of line 
PFS benefit across 
genotype or IPSSWM 
prognostic score 
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D0005: How does ibrutinib affect symptoms and findings (severity, frequen-
cy) of Waldenström’s macroglobulinemia? 
The secondary endpoint of BICR-assessed ORR in the ITT population was 
92% in the ibrutinib combination group and 47% in the placebo combina-
tion group (p < 0.0001). Major response (MR), involving complete response 
(CR), very good partial response (VGPR) (≥90% reduction in serum IgM 
levels), or partial response (PR), was noted in 72% of ibrutinib combination 
versus 32% of placebo combination participants (p < 0.0001). A very good 
partial response was reported in 23% of ibrutinib combination versus 4% of 
placebo combination patients.  
Patients with MYD88 L265P/CXCR WT or MYD88 L265P/CXCR4 WHIM 
genotypes exhibited higher ORR than those with MYD88 WT/CXCR4 WT 
genotype. The ORR rates were 94% versus 46% among patients with the 
MYD88 L265P/CXCR4 WT genotype (n = 67), 100% versus 52% among 
those with the MYD88 L265P/CXCR4 WHIM genotype (n = 49), and 81% 
versus 55% among those with the MYD88 WT/CXCR4 WT genotype (n = 
20) for the ibrutinib/rituximab arm versus the placebo/rituximab arm. 
Among those patients with partial or greater response, 92% of ibrutinib 
combination responders and 41% of placebo combination responders exhib-
ited ongoing response at 24 months. The median DOR was not reached 
(range 1.9–36.4 months) among 54 patients with at least a partial response in 
the ibrutinib combination group and was 21.2 months (range 4.6–25.8) 
among 24 patients with partial or greater response in the placebo combina-
tion group.  
After four weeks, the median IgM level was reduced from baseline by 56% 
with ibrutinib combination compared with an increase of 6% with placebo 
combination. Transient increases in IgM levels or flares were reported in 8% 
of the ibrutinib combination group and 47% of the placebo combination 
group. While 12 patients required plasmapheresis during the course of 
treatment, none were from the ibrutinib combination group. 
In the ITT population, the rate of sustained increase in Hb was 73% in the 
ibrutinib combination group and 41% in the placebo combination group (p 
< 0.0001), while that in of patients with anaemia at baseline was 95% and 
56% (p < 0.0001), respectively.  
 
D0011: What is the effect of ibrutinib on patients̕  body functions? 
Ibrutinib may cause atrial fibrillation, infection, hepatitis B reactivation, fe-
ver, tumour lysis syndrome, and new onset hypertension or hypertension 
that is not adequately controlled. Based on a pooled safety analysis, ibrutinib 
may cause grade ≥3 cytopenias, including neutropenia (14%), thrombocyto-
penia (7%), and anaemia (6%) [4]. Patients should be monitored periodical-
ly for serum creatinine levels, and monthly for complete blood counts and 
symptoms of atrial fibrillation [4]. 
 
D0012: What is the effect of ibrutinib on generic health-related quality of 
life? 
An improvement from baseline in the total score on the FACT-An was re-
ported in 73% of ibrutinib combination patients and 59% of placebo combi-
nation patients (p = 0.06). Similarly 64% of ibrutinib combination and 48% 
ORR ITT:  
ibrutinib combination: 
92% 
placebo combination: 
47%  
MYD88 L265P/CXCR WT 
or MYD88 L265P/CXCR4 
WHIM genotypes had 
greater ORR than 
MYD88 WT/CXCR4 WT 
patients 
median DOR: not 
reached for ibrutinib 
combination vs. 21.2 
months for placebo 
combination patients 
IgM flare: 
ibrutinib combination: 
8% 
placebo combination: 
47% 
increase in Hb:  
ibrutinib combination: 
73%  
placebo combination: 
41% 
atrial fibrillation, 
infection, hepatitis B 
reactivation, tumour 
lysis syndrome, 
hypertension, 
cytopenias 
FACT-An: 
 improvement from 
baseline   
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of placebo combination patients experienced an improvement in anaemia 
subscale score (p = 0.05). 
 
D0013: What is the effect of ibrutinib on disease-specific quality of life? 
No evidence reported regarding the effect of ibrutinib on disease-specific 
QoL.  
 
 
 
 
 
 
 
 
 
 
  
disease-specific QoL:  
no evidence 
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Table 1: Efficacy results of iNNOVATE [7, 30] 
Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DOR = duration of response; FACT-An = 
Functional Assessment of Cancer Therapy-Anaemia; Hb = haemoglobin; HR = hazard ratio; m = months; n = number; NA = not attained; NR = not 
reported; OR = odds ratio; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; VGPR = very good partial response; WT 
= wild type 
Descriptive sta-
tistics and 
estimate varia-
bility 
Treatment group 
Ibrutinib + rituximab 
(n = 75) 
Placebo + rituximab 
(n = 75) 
BICR-assessed 30 m OS, n (%) 71 (94) 69 (92) 
BICR-assessed median 30 m PFS, m (95% CI) 
  24 m PFS rate, n (%) treatment-naïve (n = 68) 
  24 m PFS rate, n (%) relapsed disease (n = 82) 
  30 m PFS rate, n (%) MYD88 L265P/CXCR4WT (n = 67) 
  30 m PFS rate, n (%) MYD88 L265P/CXCR4WHIM (n = 49) 
  30 m PFS rate, n (%) MYD88WT/CXCR4WT (n = 20) 
  30 m PFS rate, n (%) high risk IPSSWM (n = 57) 
  30 m PFS rate, n (%) intermediate risk IPSSWM (n = 61) 
  30 m PFS rate, n (%) low risk IPSSWM (n = 32) 
NA 
29/34 (84) 
33/41 (80) 
28/32 (86) 
21/26 (80) 
9/11 (80) 
25/27 (93) 
23/33 (70) 
13/15 (86) 
20.3 (NR) 
20/34 (59) 
15/41 (37) 
12/35 (33) 
7/23 (29) 
2/9 (21) 
7/30 (22) 
8/28 (28) 
7/17 (42) 
BICR-assessed ORR, n, % (95% CI) 
  CR, n (%) MYD88 L265P/CXCR4WT (n = 67) 
  VGPR, n (%) MYD88 L265P/CXCR4WT  (n = 67) 
  CR, n (%)MYD88 L265P/CXCR4WHIM  (n = 49) 
  VGPR, n (%)MYD88 L265P/CXCR4WHIM  (n = 49) 
  CR, n (%)MYD88WT/CXCR4WT  (n = 20) 
  VGPR, n (%)MYD88WT/CXCR4WT  (n = 20) 
69 (92), p < 0.001 
2/32 (6) 
9/32 (28) 
0/26 (0) 
5/26 (19) 
0/11 (0) 
3/11 (27) 
35 (47) 
0/35 (0) 
2/35 (6) 
1/23 (4) 
0/23 (0) 
0/9 (0) 
0/9 (0) 
BICR-assessed median DOR, n, m (range) (n = 78) n = 54 NA (1.9–36.4) n = 24, 21.2 (4.6–25.8) 
IgM flare, n (%) 6 (8) 35 (47) 
Sustained increase in Hb, n (%)  55 (73), p<0.001 31 (41) 
FACT-An (%) 73, p = 0.06 59 
Effect  
estimate per 
comparison 
 
Comparison groups                                                                                    Ibrutinib combination versus placebo combination 
BICR-assessed PFS (n = 150) 
(primary endpoint) 
HR  0.20 
95% CI 0.11–0.38 
Log-rank test p-value <0.001 
PFS, treatment-naive 
(subgroup analysis, n = 68) 
HR  0.34 
95% CI 0.12–0.95 
Log-rank test p-value <0.001 
PFS, relapsed disease 
(subgroup analysis, n = 82) 
HR  0.17 
95% CI 0.08–0.36 
Log-rank test p-value <0.001 
30 m PFS rate, (%) MYD88 L265P/CXCR4WT 
(subgroup analysis, n = 67) 
HR  0.17 
95% CI 0.06–0.49 
Log-rank test p-value <0.001 
30 m PFS rate, MYD88 L265P/CXCR4WHIM 
(subgroup analysis, n = 49) 
HR  0.24 
95% CI 0.09–0.66 
Log-rank test p-value <0.001 
30 m PFS rate, MYD88WT/CXCR4WT 
(subgroup analysis, n = 20) 
HR  0.21 
95% CI 0.04–1.08 
Log-rank test p-value <0.001 
30 m PFS rate, low risk IPSSWM   
(subgroup analysis, n = 32) 
HR  0.16 
95% CI 0.03–0.76 
Log-rank test p-value <0.001 
30 m PFS rate, intermediate risk IPSSWM   
(subgroup analysis, n = 61) 
HR  0.43 
95% CI 0.19–1.00 
Log-rank test p-value <0.001 
30 m PFS rate, high risk IPSSWM 
(subgroup analysis, n = 57) 
HR  0.07 
95% CI 0.02–0.31 
Log-rank test p-value <0.001 
Ibrutinib plus rituximab for the treatment of Waldenström’s macroglobulinemia 
LBI-HTA | 2018 21 
7.2.2 Safety 
 
C0008: How safe is ibrutinib in relation to the comparator(s)? 
In the safety population (n = 150), investigator-assessed AEs were more 
commonly reported in the ibrutinib- than placebo combination groups, re-
spectively, included diarrhoea (28% versus 15%), arthralgia (24% versus 
11%), and nausea (21% versus 12%). In contrast, IgM flare (8% versus 47%), 
infusion-related reactions (43% versus 59%), fatigue (13% versus 27%), as-
thenia (16% versus 25%), anaemia (19% versus 29%), and headache (13% 
versus 23%) were less commonly reported in the ibrutinib- than placebo 
combination group.  
Approximately 60% of patients in each group experienced at least one AE of 
≥3 severity. Hypertension (13% versus 4%) and atrial fibrillation (12% ver-
sus 1%) were more frequent in those receiving ibrutinib combination, while 
anaemia (11% versus 17%) and infusion reactions (1% versus 16%) were 
more common in those receiving placebo combination. Pneumonia (8%), 
atrial fibrillation (7%) and respiratory tract infection (4%) were the most 
common serious AEs observed with ibrutinib combination. Fatal AEs oc-
curred in no patients in the ibrutinib combination group and three patients 
in the placebo combination group.  
 
C0002: Are the harms related to dosage or frequency of applying ibrutinib? 
Median DOT was 25.8 months (range 1.0–37.2) for ibrutinib combination 
and 15.5 months (range 0.4–34.3) for placebo combination. AEs of grade ≥3 
severity were observed in 60% and 61% of patients in the ibrutinib- and pla-
cebo combination groups, respectively. Approximately 5% of ibrutinib com-
bination patients and 4% of placebo combination patients discontinued due 
to AEs. AEs led to a dose reduction in 13 (1%) ibrutinib combination pa-
tients, most commonly as a result of neutropenia (n = 3), atrial fibrillation 
(n = 2), and muscle spasm (n = 2).  
Atrial fibrillation, of any grade, occurred in 15% of ibrutinib- and 3% of pla-
cebo combination patients. Among those with atrial fibrillation, a history of 
atrial fibrillation was reported in 27% of those in the ibrutinib combination 
group and none of those in the placebo combination group.  
Bleeding events were more common in patients treated with ibrutinib- than 
placebo combination (51% versus 21%); grade 1 or 2 events occurred in 92% 
versus 81% of patients, respectively. Major haemorrhage was reported in 
three (4%) patients in each treatment group. The use of anticoagulant or an-
tiplatelet medications was more common with ibrutinib combination than 
placebo combination (43% versus 36%), respectively. One placebo combina-
tion patient experienced a fatal intracranial haemorrhage.  
 
 
 
 
 
common AEs:  
diarrhoea, arthralgia 
and nausea  
common grade ≥ 3 AEs: 
hypertension and atrial 
fibrillation 
 
serious AEs: pneumonia, 
atrial fibrillation and 
respiratory tract 
infection  
5% discontinued due to 
AEs; 1% reduced dose 
for neutropenia, atrial 
fibrillation or muscle 
spasm 
atrial fibrillation:  
15% for ibrutinib 
combination  versus 3% 
for placebo combination 
bleeding:  
51% for ibrutinib 
combination versus  
21% for placebo 
combination 
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C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of ibrutinib? 
Ibrutinib is generally avoided in patients with a history of arrhythmia, sig-
nificant hepatic impairment, severe bleeding, and in those on anticoagula-
tion [4, 35]. Study participants had a median age of 69 years (range 36–89), 
with good performance status (ECOG 0–1). Patients with a history of stroke, 
intracranial haemorrhage, CNS involvement, bleeding disorders, systemic 
infection or cardiovascular disease were excluded from study. Approximate-
ly 55% of atrial fibrillation observed in the ibrutinib combination group, 
was reported in patients aged 75 years of age or older [29].  
In pooled safety analysis, AEs of grade ≥3 severity were more frequent 
among patients aged 65 years of age and older than younger patients (73% 
versus 66%, respectively), as were AEs leading to discontinuation (14% ver-
sus 8%, respectively) and fatal AEs (8% versus 4%, respectively) [4]. Events 
more commonly reported in patients 65 years of age and older compared 
with younger patients included thrombocytopenia, pneumonia, urinary tract 
infection, hypertension, atrial fibrillation, and hyponatraemia [4].  
Ibrutinib may cause foetal harm and potential for serious AEs in nursing in-
fants. Females are advised to use highly effective contraceptives and to dis-
continue breastfeeding during ibrutinib treatment. Males are advised not to 
father a child while receiving ibrutinib, and for three months following 
completion of treatment [4]. Depending on the type and risk of bleeding, ib-
rutinib should be held three to seven days pre- and post-surgery. 
susceptibles:  
elderly; history of atrial 
fibrillation, hepatic 
impairment, 
anticoagulants or 
platelet inhibitors 
common AEs in elderly: 
thrombocytopenia, 
pneumonia, urinary 
tract infection, 
hypertension, atrial 
fibrillation, and 
hyponatraemia 
ibrutinib may cause 
foetal harm; hold pre- 
and post-operatively 
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Table 2: Most frequent adverse events [7, 29] 
 
Adverse Event (according  
to CTCAE version 4.03) 
 
Ibrutinib-Rituximab  
(n = 75) 
Placebo-Rituximab  
(n = 75) 
Most common AEs of any grade n (%) 
AEs, n (%) 75 (100) 75 (100) 
   Infusion-related reaction 32 (43) 44 (59) 
   Diarrhoea 21 (28) 11 (15) 
   Arthralgia 18 (24) 8 (11) 
   Nausea 16 (21) 9 (12) 
   Anaemia 14 (19) 22 (29) 
   Hypertension 14 (19) 4 (5) 
   Asthenia 12 (16) 19 (25) 
   Atrial fibrillation 11 (15) 2 (3) 
   Fatigue 10 (13) 20 (27) 
   Headache 10 (13) 17 (23) 
   IgM flare 6 (8) 35 (47) 
Grade ≥ 3 AEs n (%) 45 (60) 46 (61) 
   Hypertension 10 (13) 3 (4) 
   Atrial fibrillation 9 (12) 1 (1) 
   Anaemia 8 (11) 13 (17) 
   Neutropenia 7 (9) 2 (3) 
   Pneumonia 7 (9) 2 (3) 
   Hyponatremia 4 (5) 2 (3) 
   Fatigue 2 (3) 1 (1) 
   Infusion-related reaction 1 (1) 12 (16) 
   Thrombocytopenia 0 (0) 4 (5) 
   Asthenia 0 (0) 2 (3) 
   Diarrhoea 0 (0) 1 (1) 
   IgM flare 0 (0) 2 (3) 
Serious AEs n (%) 32 (43) 25 (33) 
   Pneumonia 6 (8) 2 (3) 
   Atrial fibrillation 5 (7) 1 (1) 
   Respiratory tract infection 3 (4) 0 (0) 
   Anaemia 2 (3) 0 (0) 
   Congestive cardiac failure 2 (3) 0 (0) 
   Fall 2 (3) 0 (0) 
   Gastroenteritis 2 (3) 0 (0) 
   Myocardial ischemia 2 (3) 0 (0) 
   Arthralgia 2 (3) 0 (0) 
Abbreviations: AE = adverse event; CTCAE = common terminology for cancer adverse events; IgM = immunoglobulin M 
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7.3 Clinical effectiveness and safety –  
further studies 
NCT01614821 is a multicentre, open-label, prospective, phase II study to 
evaluate the safety and efficacy of ibrutinib in 63 symptomatic patients with 
previously treated WM, and investigate the influence of MYD88 and 
CXCR4 mutations on outcomes [6]. Patients received 420 mg of ibrutinib 
orally once daily for twenty-six 4-week cycles until progression or unac-
ceptable toxicity. The primary endpoint was BICR-assessed ORR, defined as 
the sum of minor responses (≥25% reduction in serum IgM levels), partial 
responses (≥50% reduction in serum IgM levels), very good partial respons-
es (≥90% reduction in serum IgM levels), and complete responses (100% 
reduction in serum IgM levels). Responses were defined according to criteria 
adopted from the Third International Workshop on WM. The secondary 
endpoints were to determine PFS and safety. A total of 63 consecutive eligi-
ble patients contributed to the efficacy and safety population. The median 
DOT was 19.1 months (range 0.5–29.7); 43 (68%) patients continued therapy 
after the database was locked December 19, 2014.  
The study population (n = 63) had a median age of 63 years (range 44–86), 
76% were male, 78% had an intermediate or high prognostic score, median 
bone marrow (BM) involvement of 60% (range 3–95), and a median of 74 
months since diagnosis. Patients with relapsed disease had received a medi-
an of two prior therapies (range 1–9); of these, 85% were previously treated 
with a monoclonal antibody. At baseline, the median serum IgM level was 
3.5 g/dL (range 0.7–8.4). Of the 62 patients for whom baseline mutational 
data were available, 89% were MYD88 L265P and 34% were CXCR4 
WHIM.   
Median serum IgM levels decreased from 3,520 mg/dL to 880 mg/dL and 
Hb levels increased from 10.5 g/dL to 13.8 g/dL. BM involvement decreased 
from 60% to 25 % (p < 0.01). The median time to a minor response was four 
weeks. At a median DOT of 19.1 months (range 0.5–29.7), the ORR was 
90.5% and the major response rate was 73.0%. Response was highest among 
patients with MYD88 L265P/CXCR4 WT (100.0% ORR and 91.2% major 
response rate), followed by MYD88 L265P/CXCR4 WHIM (85.7% and 
61.9%, respectively), and patients with MYD88 WT/CXCR4 WT (71.4% and 
28.6%, respectively). Estimated 2-year PFS and OS rates among all patients 
were 69.1% (95% CI 53.2–80.5) and 95.2% (95% CI 86.0–98.4), respectively. 
Among patients with progressive disease, the median time to progression 
was 9.6 months (range 3.5–19.4). Subgroup analysis suggests that a high 
IPSS score, greater than three previous treatment regimens, and a MYD88 
WT/CXCR4 WT genotype were associated with lower rates of PFS. Treat-
ment-related AE of grade ≥2 severity included neutropenia (22%) and 
thrombocytopenia (14%), which were more common in heavily pre-treated 
patients; post-procedural bleeding (3%); epistaxis associated with use of 
fish-oil supplements (3%); and atrial fibrillation associated with a history of 
arrhythmia (5%). AEs resulted in dose reductions in ten patients.  
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8 Estimated costs 
A0021: What is the reimbursement status of ibrutinib? 
In Austria, ibrutinib is available in 90- and 120-capsule bottles of 140 mg 
capsules for € 5,474.70 and € 7,299.60, respectively [23]. At the recommend-
ed dosage of 420 mg (three 140 mg capsules) per day, a median duration of 
treatment of 25.8 months would cost approximately € 141,247.26. Ibrutinib 
therapy is administered in combination with two four-week courses of ritux-
imab (375 mg/m
2
 IV) every five months, at an additional cost of approxi-
mately € 85,196.00 per median duration of treatment of 25.8 months [31]. 
Overall, it would cost approximately € 226,443.26 to treat each WM patient 
with ibrutinib in combination with rituximab. Since close to 26 patients are 
diagnosed with WM in Austria annually [23], and approximately 91% have 
MDY88 L265P mutations that could benefit from therapy [6], ibrutinib in 
combination with rituximab would cost approximately € 5,357,647.50 per 
year. Additional costs to assess the mutational status of MYD88 and CXCR4 
will incur. 
 
 
 
9 Ongoing research 
A few studies are ongoing to investigate ibrutinib as monotherapy or in 
combination with other targeted therapies for treatment naïve WM and 
those with relapsed disease. In November 2018, searches of 
www.clinicaltrials.gov and www.clinicaltrialsregister.eu using the search 
terms “ibrutinib” and “Waldenstrom Macroglobulinemia” yielded 14 other 
registered studies (two phase III, six phase II, one phase I/II, and five phase 
I studies). Most studies were industry-sponsored or conducted in collabora-
tion with industry. 
Selected ongoing phase III, II, II/I, and I studies evaluating ibrutinib in 
combination with rituximab and bendamustine, or pembrolizumab for re-
lapsed or refractory WM, versus zanubrutinib for WM, in hepatitis B carri-
ers with relapsed or refractory WM, in previously untreated WM in relation 
to tumour genomic evolution, in combination with daratumumab, as first-
line with bortezomib and rituximab for WM, in combination with ulo-
cuplumab in WM patients with CXCR4 mutations, and in combination with 
ixazomib for relapsed or refractory disease: 
 NCT01479842: is a phase I, open-label, single-group, interventional 
study to evaluate the activity of combined rituximab, benda-
mustine, and ibrutinib in patients with relapsed and refractory B-
cell NHL, including WM. Estimated study completion date is De-
cember 2018. 
 NCT02332980: is a phase II, open-label, single-group, intervention-
al study to explore the efficacy of pembrolizumab alone or in com-
bination with idelalisib or ibrutinib for patients with low-grade B-
€ 226,443.26  
per patient for  
25.8 months  
of ibrutinib + rituximab 
therapy  
14 registered studies 
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cell non-Hodgkin lymphomas, including WM. Estimated study 
completion date is January 2020. 
 NCT03053440: is a phase III, randomised, open-label, multicentre 
study comparing the safety and efficacy of the BTK inhibitors za-
nubrutinib and ibrutinib in patients with WM. Estimated study 
completion date is June 2021. 
 NCT02991638: is a phase III, randomised, open-label, intervention-
al study to assess the safety and efficacy of ibrutinib in hepatitis B 
carriers with relapsed/refractory lymphocytic leukaemia or WM Es-
timated study completion date is June 2021. 
 NCT02604511: is a phase II, open-label, single-group, intervention-
al study to investigate the safety and efficacy of ibrutinib in un-
treated WM patients and to identify genetic changes that effect how 
ibrutinib works using genomic sequencing. Estimated study com-
pletion date is February 2023. 
 NCT03679624: is a phase II, non-randomised, open-label, cohort 
study to evaluate the effectiveness of adding daratumumab to ibru-
tinib for WM. Estimated study completion date is November 2023. 
 NCT03620903: is a phase II, open-label, single-group, intervention-
al study to assess the toxicity and efficacy of bortezomib, rituximab 
and ibrutinib (B-RI) for treatment-naïve WM. Estimated study 
completion date is November 2024. 
 NCT03225716: is a phase I/II, open-label, single-group, interven-
tional study to evaluate the safety, dosage, and ORR of ulo-
cuplumab and ibrutinib in symptomatic patients with mutated 
CXCR4 WM. Estimated study completion date is January 2025. 
 NCT03506373: is a phase II, open-label, single-group, intervention-
al study to explore the effectiveness of ibrutinib in combination 
with ixazomib for relapsed or refractory WM. Estimated study 
completion date is May 2025. 
 
 
 
10 Discussion 
In January 2015, both the FDA and the EMA licensed ibrutinib as mono-
therapy for the treatment of relapsed or refractory WM, or as first-line ther-
apy for patients unsuitable for immunochemotherapy [13]. Approval was 
based on the ORR reported in a phase II multicentre cohort study [6]. In 
August 2018, the FDA approval was expanded to include combination use 
with rituximab across all lines of therapy for WM based on 30-month PFS 
rates reported in the phase III iNNOVATE trial [7, 8]. There is no indica-
tion as to when the EMA may receive a MAA to extend the use of ibrutinib 
in combination with rituximab for WM. Ibrutinib is also currently approved 
by the FDA and EMA for use as second-line for MCL, any-line monotherapy 
for CLL, second-line in combination with bendamustine and rituximab for 
CLL and SLL, and GVHD [4, 14].  
FDA and EMA: 
monotherapy for WM  
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rituximab for WM 
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iNNOVATE, a double-blind, randomised, phase III study investigated 
whether adding ibrutinib to rituximab prolongs PFS and ORR in 150 symp-
tomatic WM patients, 68 of whom had disease recurrence [7]. Stratified by 
prognostic score, number of prior treatments and ECOG status, participants 
were randomised 1:1 to 420 mg oral ibrutinib or placebo until disease pro-
gression or toxicity. Patients also received 375 mg/m
2
 rituximab IV once 
weekly for four weeks, followed by another four-week course after a three-
month interval. Adding ibrutinib prolonged PFS by 54%, conferring a long-
er PFS than rituximab alone at 26.5 months (not reached versus 20.3 
months, respectively) and reducing the relative risk of progression or death 
by 80%. The PFS benefit was observed regardless of previous treatment, 
MYD88 or CXCR4 genotype, or prognostic score. At 30 months, the OS rates 
were 94% versus 92% for ibrutinib- and placebo combination, respectively; 
median OS was not reached in either group. Adding ibrutinib to rituximab 
increased the ORR by 45% compared with rituximab alone with robust re-
sponse rates across all genotypes. Adding ibrutinib to rituximab therapy in-
creased the number of patients with sustained Hb by 32% and resulted in 
fewer IgM flares (8% versus 47%, respectively). Ibrutinib combination in-
creased the FACT-An by 14% and the anaemia subscale score by 16%.  
Commonly reported AEs in ibrutinib combination patients compared to 
rituximab alone included diarrhoea, arthralgia, and nausea. Hypertension 
and atrial fibrillation were the most common AEs of grade ≥3 severity. The 
most common serious AEs observed with ibrutinib combination include 
pneumonia (8%), atrial fibrillation (7%), and respiratory tract infection 
(4%). AEs led to a dose reduction in 13 ibrutinib combination recipients, 
most commonly as a result of neutropenia, atrial fibrillation, or muscle 
spasm. Atrial fibrillation and bleeding events were 12% and 30% more 
common in the ibrutinib combination versus rituximab alone.  
The results of iNNOVATE hold some limitations. Follow-up is insufficient 
to evaluate OS and long-term safety. No evidence was reported regarding the 
effect of ibrutinib combination on disease-specific QoL. Mature OS data and 
disease-specific QoL measures are needed to ensure patients achieve a clini-
cally relevant benefit over time despite manageable toxicity. The large con-
fidence intervals associated with some subgroup analyses such as that for 
PFS of MYD88 WT/CXCR4 WT, or low prognostic score suggest a larger 
sample size would be needed to gain greater precision regarding the effect of 
these factors on outcomes.  
Generalizability may be limited in that the study population had good per-
formance status (ECOG ≤1: n = 140/150), those with relapsed disease re-
ceived a median of two prior therapies, and of these, were rituximab sensi-
tive. Patients with CNS involvement, cardiovascular disease, bleeding disor-
ders, infections, stroke or intracranial haemorrhage were excluded from 
study. The applicability of these study results for patients with higher 
ECOG performance status, cardiac risk factors, hypertension, bleeding, or 
rituximab resistance needs further evaluation. While MYD88 and CXCR4 
mutation status influenced response to ibrutinib, other biomarkers warrant 
further investigation in defining possible responders to treatment. While 
rituximab is a suitable comparator, bendamustine and rituximab may also 
be appropriate as first-line therapy, bortezomib-rituximab-dexamethasone is 
suitable for those with symptomatic hyperviscosity, and ofatumumab is ap-
propriate for previously-treated WM intolerant to rituximab. Without direct 
comparison trials, physicians and patients may need to discuss whether add-
iNNOVATE 
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ing ibrutinib to rituximab would provide greater individualised efficacy 
than ibrutinib monotherapy.  
iNNOVATE is a phase III trial with few methodological limitations. There 
was no risk of bias in the generation of randomisation sequence or allocation 
concealment. Patients were randomly assigned 1:1 to ibrutinib combination 
or placebo combination using a web-based response system [5]. Patients, 
physicians, and outcome assessors were blinded as patients received ibru-
tinib or matching placebo on an outpatient basis. Selective reporting is un-
likely as the primary endpoint of PFS, secondary endpoints of OS, ORR, Hb 
TTNT, QoL and safety were reported as specified in the protocol. The risk 
of bias may be increased by cross-over (30 patients switched to ibrutinib 
monotherapy after progression), and industry involvement in funding the 
study, collecting, confirming and compiling data for analysis, and drafting 
and reviewing the manuscript. 
The efficacy and safety data from iNNOVATE are consistent with a previ-
ously reported phase II study suggesting ibrutinib monotherapy reduces se-
rum IgM, increases Hb, and confers ORR, PFS and OS rates in the range of 
90.5%, 69.1%, and 95.2%, respectively, in refractory WM patients [6]. While 
IPSSWM risk factors were developed to predict OS, increased PFS was ob-
served across prognostic scores in the iNNOVATE trial. In the previous 
phase II study, mutations in MYD88 and CXCR4 influenced response to ib-
rutinib monotherapy, whereas response rates with ibrutinib combination 
were similar across different CXCR4 genotypes but lower among patients 
lacking the activating MYD88 L265P mutation. While minor differences in 
response rates with regards to the MYD88/CXCR4 genotypes did not affect 
the PFS benefit observed with ibrutinib combination, authors recommend 
exercising caution due to small sample size. Rates of atrial fibrillation with 
ibrutinib combination were similar to those reported in long-term follow-up 
for ibrutinib monotherapy.  
A few studies are underway to investigate ibrutinib as monotherapy or in 
combination with other targeted therapies for symptomatic untreated WM 
and those with relapsed disease. Ongoing phase III studies are evaluating 
the comparative effectiveness of zanubrutinib versus ibrutinib for WM, and 
the efficacy of ibrutinib in hepatitis B carriers with refractory WM. Phase II 
studies are investigating the efficacy of pembrolizumab alone or in combina-
tion with idelalisib or ibrutinib; the addition of daratumumab to ibrutinib 
for WM; ibrutinib in combination with ixazomib for refractory disease; and 
the genetic changes that affect the efficacy of ibrutinib in untreated WM. 
Phase I studies are exploring the activity of combined rituximab, benda-
mustine and ibrutinib in WM, and the safety and ORR of ulocuplumab and 
ibrutinib in symptomatic patients with mutated CXCR4 WM. 
At the recommended dosage of 420 mg (three 140 mg capsules) of ibrutinib 
per day, a median DOT of 25.8 months would cost approximately € 
141,247.26 [23]. Ibrutinib therapy is administered in combination with two 
four-week courses of rituximab (375 mg/m
2
 IV) every five months, at an ad-
ditional cost of approximately € 85,196.00 per median DOT of 25.8 months 
[31]. Overall, it would cost approximately € 226,443.26 to treat each WM pa-
tient with ibrutinib in combination with rituximab. Since close to 26 pa-
tients are diagnosed with WM in Austria annually [23], and approximately 
91% have MDY88 L265P mutations that could benefit from therapy [6], ib-
rutinib in combination with rituximab would cost approximately € 
low risk of bias: 
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5,357,647.50 per year. Additional costs to assess the mutational status of 
MYD88 and CXCR4 will incur. 
Ibrutinib-related AEs result from binding to other tyrosine-protein kinases 
(TEC) and epidermal growth factor receptors (EGFR). There is uncertainty 
as to which side effects are due to on-target BTK inhibition in nonlympho-
ma tissues versus off-target kinase inhibition. There is evidence of higher 
BTK/TEC expression in the myocardium of AF patients versus those with 
sinus rhythm, and ibrutinib inhibits the transduction of cardioprotective 
PI3K/AKT signalling. AEs and the development of ibrutinib resistance have 
led to the development of more specific BTK inhibitors, such as za-
nubrutinib (BGB-3111), ONO/GS-4059, acalabrutinib (ACP-196), and 
vecabrutinib (SNS-062). Approximately 50% of WM patients that progress 
on ibrutinib acquire new mutations on cysteine 481 of the BTK gene that ab-
rogate binding of the drug to the protein while mediating cell survival 
through sustained ERK phosphorylation and pro-inflammatory cytokine se-
cretion. Given the need for indefinite continuous treatment, fewer AEs may 
reduce discontinuation and prolong PFS for WM patients. While new inhib-
itors, like CXCR4-blocking antibody vecabrutinib may overcome acquired 
BTK C481S-induced ibrutinib resistance, it would not overcome PLC2-
induced and ARD11-mutation-induced resistance. It is unclear whether any 
new BTK inhibitor can induce complete remission in WM patient; ibrutinib 
in synergistic combination with IRAK, SYK or Src kinase inhibitors may be 
more potent. A combinatorial approach could target different aspects of cell 
biology resulting in superior clinical response compared with BTK inhibitor 
monotherapy [2].  
Overall, iNNOVATE is the first phase III, randomised, double-blind study 
to demonstrate that adding ibrutinib to rituximab therapy increases PFS 
and ORR in symptomatic untreated WM and those with relapsed/refractory 
disease. The PFS and ORR benefits of ibrutinib combination over rituximab 
alone were consistent across subgroups regardless of line, genotype or prog-
nostic score. Adding ibrutinib to rituximab therapy increased the number of 
patients with sustained Hb and reduced IgM flares. Data regarding OS is 
needed to ensure patients derive a clinically relevant benefit over time de-
spite manageable toxicity. However, it is very unlikely that this study is ap-
propriate to demonstrate a potential OS benefit because of the possibility of 
crossover to ibrutinib for patients with progression upon rituximab/placebo 
treatment. Biomarkers would ensure the appropriate selection of patients 
most likely to benefit from treatment. Further evaluation is needed to iden-
tify the role of ibrutinib as first-line versus salvage therapy; monotherapy 
versus in combination with biologic agents, other small molecules or chemo-
immunotherapy; optimal duration of treatment; management of ibrutinib 
intolerant or resistant patients; and the comparative safety and effectiveness 
with new BTK inhibitors. 
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12 Appendix  
Table 3: Administration and dosing and of ibrutinib or placebo + rituximab [4, 5, 7, 14] 
 Ibrutinib + rituximab Placebo + rituximab 
Administration 
mode 
Swallow oral capsules whole with 8 ounces of water, 
with or without food, once daily at approximately 
the same time each day [4]. 
Matching placebo [7] 
Description of 
packaging 
140 mg white capsules marked “ibr 140 mg” in black 
ink packaged in HDPE bottles of 90 or 120 capsules 
[4]; 4-week blister packs of 140 mg, 280 mg, 420 mg 
and 560 mg film-coated tablets [14] 
Matching placebo [7] 
Total volume con-
tained in packaging 
for sale 
90- and 120-capsule bottles of 140 mg capsules con-
tain 90 and 120 capsules, respectively (140 mg per 
capsule, 3 x 140 mg capsules once daily [4];  
Matching placebo [7] 
Dosing 
420 mg ibrutinib (3 x 140 mg capsules) once daily 
until progression or unacceptable toxicity [4]; dosed 
0-30 minutes before rituximab infusion on week 4. 
Patients received rituximab (375 mg/m2 IV at weeks 
1-4 and 17-20) [5]. Withhold for grade ≥3 non-
haematological toxicities, grade ≥3 neutropenia with 
infection or fever, or grade 4 haematological toxici-
ties; resume once symptoms resolve to grade 1 or 
baseline. If toxicity reoccurs, reduce dose by one cap-
sule (140 mg/day). Discontinue if toxicities persist or 
recur following two dose reductions [4]. 
Matching placebo, identical admin-
istration. Patients received rituximab 
(375 mg/m2 IV at weeks 1-4 and 17-20) 
[5]. Withhold for grade ≥3 non-
haematological toxicities, grade ≥3 
neutropenia with infection or fever, 
or grade 4 haematological toxicities; 
resume once symptoms resolve to 
grade 1 or baseline. If toxicity reoc-
curs, reduce dose by one capsule (140 
mg/day). Discontinue if toxicities per-
sist or recur following two dose re-
ductions [4]. 
Median treatment 
duration, m (range) 
Until progression or unacceptable toxicity; median 
DOT: 25.8 months (1.0-37.2) 
Until progression or unacceptable 
toxicity; cross-over to ibrutinib per-
mitted after BIRC-assessed progres-
sion; median DOT: 15.5 months (0.4-
34.4) 
Contraindications 
Not for use in patients with moderate or severe he-
patic impairment (Child-Pugh class B or C). Reduce 
dose to 140 mg in patients with mild hepatic im-
pairment  [4]. 
Not for use in patients with moderate 
or severe hepatic impairment (Child-
Pugh class B or C). Reduce dose to 140 
mg in patients with mild hepatic im-
pairment [4]. 
Drug interactions 
Avoid CYP3A inhibitors/inducers, grapefruit and Se-
ville oranges. Hold or reduce dose to 140 mg ibru-
tinib for duration of strong or moderate CYP3A 
treatment. Take digoxin ≥6 hours before or after ib-
rutinib; monitor ECG and electrolytes when using 
medications that prolongs QT. Caution in subjects on 
anticoagulants or platelet inhibitors [4].  
Matching placebo [7] 
Abbreviations: BIRC = blinded independent review committee; DOT = duration of treatment; ECG = electrocardiogram; HDPE = 
high-density polyethylene; IV = intravenous 
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Table 4: Characteristics of the iNNOVATE trial [7] 
Title: Ibrutinib with rituximab in adults with WM (iNNOVATE) [5, 7, 30] 
Study identifier NCT02165397, EUDRACT2013-005478-22, PCYC-1127-CA, iNNOVATE 
Design International (9 countries), multicentre (45 sites), randomised, double-blind, interventional phase III 
Duration of treatment phase: July 2014 – January 2016, time from randomisation to end 
of treatment visit (30 days from last day of study treatment 
or prior a new anticancer treatment). Treatment occurs 
within 72 hours of randomisation. Data from interim analy-
sis at 30 months. 
Duration of screening phase: 30 days prior to study treatment; subjects meeting inclu-
sion criteria are eligible for study  
Duration of extension phase: After end-of-treatment visit, subjects are monitored every 
12 weeks through response follow-up or survival follow-up 
until death, loss to follow-up, consent withdrawal, or study 
end.  
Hypothesis 
Superiority 
The primary hypothesis is that ibrutinib in combination with rituximab will result in an improvement in 
PFS compared to placebo in combination with rituximab in subjects with symptomatic WM. 
Funding Pharmacyclics and Janssen Research and Development 
Treatments groups 
 
Ibrutinib + rituximab (Arm A, RCT) 
(n = 75 efficacy; n = 75 safety) 
Ibrutinib: 420 mg (3 oral capsules x 140 mg) administered 
daily beginning from day 1 
Rituximab: 375 mg/m2 IV once weekly for four consecutive 
weeks (weeks 1-4), followed by a second four-weekly ritux-
imab course after a three-month interval (weeks 17-20). 
Placebo + rituximab (Arm B, RCT) 
(n = 75 efficacy; n = 75 safety) 
Placebo: 3 matching oral capsules administered daily begin-
ning from day 1 
Rituximab: 375 mg/m2 IV once weekly for four consecutive 
weeks (weeks 1-4), followed by a second four-weekly ritux-
imab course after a three-month interval (weeks 17-20). 
Ibrutinib (Arm C, open label sub-study) (n 
= NR efficacy; n = NR safety) 
Ibrutinib: 420 mg (3 oral capsules) administered daily be-
ginning from day 1 
 
Notes 
MYD88 and CXCR4 mutation status was assessed in bone 
marrow samples prior to starting treatment. Treatment 
continued until progression or unacceptable toxicity. Place-
bo + rituximab patients were permitted to cross-over to re-
ceive ibrutinib after BIRC-assessed progression (n = 30). 
Since treatment-naïve patients were enrolled after a proto-
col amendment, 30 m PFS rates could not be estimated 
among these patients.  
Endpoints and defi-
nitions 
 
Progression-free survival 
Primary endpoint  PFS 
Time from randomisation until progression or death (up to 
3 years), as assessed by BICR, based on the modified Con-
sensus Response Criteria from the VIth IWWM (NCCN 2014) 
Overall survival 
Secondary endpoint OS Time from randomisation until all-cause death up to 3 years 
Overall response rate 
Secondary endpoint ORR 
Number (%) of patients with confirmed CR or PR, as as-
sessed by BIRC, based on the modified VIth IWWM (NCCN 
2014) criteria 
Haematological improvement 
Secondary endpoint Hb 
Number (%) of patients with sustained HgB improvement, 
as measured by an increase from baseline ≥ 2 g/dL or for pa-
tients with baseline anaemia, an increase to a HgB >11 g/dL 
for ≥  56 days without transfusion or growth factors 
Time to next treatment 
Secondary endpoint 
TTNT Time from randomisation to start date of any subsequent 
WM treatment (up to 3 years) 
Quality of life 
Secondary endpoint QoL 
Proportion of subjects with ≥ 3 points increase from base-
line by week 25 in the FACIT-Fatigue subscale score. 
FACT-An total score and anaemia subscale score; clinically 
meaningful improvement defined as an increase of ≥ 7 
points in FACT-An total score and ≥ 6 points in anaemia 
subscale score. 
Adverse events 
Secondary endpoint AEs 
AEs graded by CTCAE version 4.03, up to 30 days following 
last dose of study drug 
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Title: Ibrutinib with rituximab in adults with WM (iNNOVATE) [5, 7, 30] 
Study identifier NCT02165397, EUDRACT2013-005478-22, PCYC-1127-CA, iNNOVATE 
 
Investigator-assessed PFS 
Investigator-assessed ORR  
Duration of response 
Clinical response rate 
Minor response 
Medical resource utilization 
Immunoglobulin M 
Bone marrow tumour 
Lymph and spleen function 
Exploratory endpoints 
PFS 
ORR 
DOR 
CRR 
MR 
MRU 
IgM 
— 
— 
Investigator-assessed progression-free survival 
Investigator-assessed overall response rate 
Time of response to until BICR-assessed progression or 
death 
Number (%) achieve ≥  minor response   
Criteria from the VIth IWWM (NCCN 2014) 
Plasmapheresis, blood transfusions, growth factors 
Median immunoglobulin M 
Presence of bone marrow tumour 
Function of lymph and spleen 
Database lock Last update posted May 8, 2018 
Results and Analysis 
Analysis description Primary Analysis 
ITT: efficacy analyses included all patients randomised. Safety analysis included all patients who received 
at least one dose of study drug (rituximab, ibrutinib/placebo).  
Primary analysis for PFS was a 2-sided log-rank test stratified according to IPSSWM (low, intermediate, 
high) and number of prior regimens (0, ≥ 1). Alpha spending for PFS was determined based on the actual 
information fraction using the O’Brien-Fleming boundary. Kaplan-Meier was used to estimate the PFS 
distribution; HR for ibrutinib versus placebo and associated 95% CI was calculated based on the stratified 
Cox proportional hazards model. Subgroup analyses of PFS are based on an un-stratified Cox model.  
Secondary end points were tested at the 2-sided significance level of 0.05 in a sequential hierarchical 
manner based on a closed testing procedure. ORR and haematological improvement were compared us-
ing the stratified Cochran-Mantel-Haenszel chi-square test. TTNT was analysed using stratified or un-
stratified log-rank as appropriate. OS analysed using stratified log-rank. OS and median OS distribution 
with 95% CI were estimated using the Kaplan-Meier product-limit method. 
A target HR for progression or death of 0.50, with 71 events provided a power of 80% based on 2-sided 
log-rank test at an alpha of 0.5. Study results represent the pre-interim analysis planned after approxi-
mately 60% (n = 42) events of BICR-assessed progression or death. Final PFS analysis is scheduled fol-
lowing approximately 70 BICR-assessed events.  
Analysis population   
Inclusion  (Arms A & B, RCT) 
 Untreated or previously treated WM; previous-
ly treated subjects must have documented pro-
gression or no response to recent treatment. 
 Centrally confirmed diagnosis of WM 
 Measurable disease defined as serum monoclo-
nal IgM >0.5 g/dl 
 Symptomatic disease meeting ≥ 1 recommenda-
tions from the 2nd IWWM for requiring treat-
ment 
 Haematology and biochemical values within 
protocol-defined limits 
 Men and women ≥ 18 years of age 
 EGOG performance status ≤ 2 
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Title: Ibrutinib with rituximab in adults with WM (iNNOVATE) [5, 7, 30] 
Study identifier NCT02165397, EUDRACT2013-005478-22, PCYC-1127-CA, iNNOVATE 
 
Exclusion 
 Known CNS involvement  
 Rituximab-resistant disease, defined as: relapse 
after last rituximab-containing therapy <12 
months since last dose, or failure to achieve a 
MR after the last rituximab-containing thera-
py. If the subject meets this exclusion criterion 
and is excluded from the main randomized 
study, participation in the non-randomized 
sub-study (Arm C) may be considered. 
 Rituximab treatment within 12 months of first 
dose of study drug 
 Known anaphylaxis or IgE-mediated hypersen-
sitivity to murine proteins or component of 
rituximab 
 Prior exposure to ibrutinib or other BTK inhibi-
tors 
 Known bleeding disorders (e.g., von Wil-
lebrand’s disease) or haemophilia 
 History of stroke or intracranial haemorrhage 
within 12 months prior to enrolment 
 Any uncontrolled active system infection 
 Any life-threatening illness, medical condition, 
or organ system dysfunction that, in the inves-
tigator’s opinion could compromise the sub-
ject’s safety or put the study outcomes at un-
due risk 
 Currently active, clinically significant CVD 
 Requires treatment with a strong cytochrome 
P450 (CYP) 3A inhibitor 
Inclusion (Arm C, open-label sub-study)  Identical to those of the randomised study, but 
subjects need to be considered refractory to 
the last prior rituximab-containing therapy de-
fined as either: relapse after the last rituximab-
containing therapy <12 months since last dose 
of rituximab, or failure to achieve at least a MR 
after last rituximab-containing therapy.  
 
Characteristics 
 
Ibrutinib-
Rituximab 
(n = 75) 
Placebo-
Rituximab 
(n = 75) 
Total 
(n = 150) 
Age 
  Median age (range), years 
  ≥ 75 years, n (%) 
 
70 (36-89) 
30 (40) 
 
68 (39-85) 
20 (27) 
 
69 (36-89) 
50 (33) 
Male, n (%) 45 (60) 54 (72) 99 (66) 
Median time from diagnosis (range), months 50 (1–257) 56 (1–247) 53 (1–257) 
ECOG performance-status, n (%) 
  0 
  1 
  2 
 
39 (52) 
32 (43) 
4 (5) 
 
37 (49) 
32 (43) 
6 (8) 
 
76 (51) 
64 (43) 
10 (7) 
Prognostic score, n (%) 
  Low 
  Intermediate 
  High 
 
15 (20) 
33 (44) 
27 (36) 
 
17 (23) 
28 (37) 
30 (40) 
 
32 (21) 
61 (41) 
57 (38) 
Genotype, n/N (%) 
  MYD88WT/CXCR4 WT 
  MYD88L265P/CXCR4 WT 
  MYD88L265P/CXCR4 WHIM 
 
11/69 (16) 
32/69 (46) 
26/69 (38) 
 
9/67 (13) 
35/67 (52) 
23/67 (34) 
 
20/136 (15) 
67/136 (49) 
49/136 (36) 
Disease-related symptoms, n (%) 
  Fatigue 
  Constitutional symptoms 
  Hyperviscosity 
 
42 (56) 
19 (25) 
9 (12) 
 
49 (65) 
29 (39) 
10 (13) 
 
91 (61) 
48 (32) 
19 (13) 
Cytopenia at baseline, n (%) 
  Hb ≤ 11 g/dl 
  Platelets ≤ 100,000/mm3 
  Absolute neutrophils ≤ 1500/mm3 
 
44 (59) 
4 (5) 
4 (5) 
 
50 (67) 
7 (9) 
1 (1) 
 
94 (63) 
11 (7) 
5 (3) 
Median Hb (range), g/dl 10.5 (6.9–15.5) 10.0 (6.6–16.1) 10.3 (6.6–16.1) 
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Title: Ibrutinib with rituximab in adults with WM (iNNOVATE) [5, 7, 30] 
Study identifier NCT02165397, EUDRACT2013-005478-22, PCYC-1127-CA, iNNOVATE 
Bone marrow infiltration 
  Median cellularity (range), % 
  Median intrabecular space (range), % 
 
80(25–100) 
36 (2–95) 
 
80 (2–100) 
40 (1–95) 
 
80 (2–100) 
38 (1–95) 
Serum IgM 
  Median (range), g/litre 
  ≥ 70 g/litre, n (%) 
  ≥ 50 g/litre, n (%) 
 
32.9 (6.2–77.6) 
2 (3) 
17 (23) 
 
31.8 (5.9–83.3) 
4 (5) 
15 (20) 
 
32.4 (5.9–83.3) 
6 (4) 
32 (21) 
Median ß2 microglobulin (range), mg/litre 3.4 (1.4–27.9) 3.9 (1.5–11.6) 3.7 (1.4–27.9) 
Extramedullary disease, n (%) 
  Adenopathy 
  Splenomegaly 
59 (79) 
56 (75) 
9 (12) 
60 (80) 
58 (77) 
18 (24) 
119 (79) 
114 (76) 
27 (18) 
Previous systemic therapies, n (%) 
  0 
  1 or 2 
  ≥ 3 
 
34 (45) 
34 (45) 
7 (9) 
 
34 (45) 
36 (48) 
5 (7) 
 
68 (45) 
70 (47) 
12 (8) 
Previous rituximab-containing regimen, n/N (%) 36/41 (88) 34/41 (83) 70/82 (85) 
Applicability of evidence 
Population 
iNNOVATE was conducted in treatment-naïve WM patients and those with rituximab-sensitive disease 
recurrence with good performance-status (ECOG ≤ 2). The applicability of these results for patients with 
higher ECOG performance-status, cardiac risk factors, hypertension, bleeding or rituximab resistance 
needs further evaluation.  
Intervention 
The dosage and administration of ibrutinib and rituximab used in iNNOVATE is consistent with that rec-
ommended for the treatment of WM [4]. Dose reduction or interruptions were allowed for any poten-
tially study drug-related event and discontinued if toxicities persist. 
Comparators 
Rituximab is indicated for symptomatic untreated WM. However, bendamustine and rituximab may also 
be appropriate as first-line therapy, bortezomib-rituximab-dexamethasone for symptomatic hyperviscosi-
ty, and ofatumumab in previously-treated WM intolerant to rituximab. Without direct comparison trials, 
physicians and patients may need to discuss whether adding ibrutinib to rituximab therapy would provide 
greater individualised efficacy than ibrutinib monotherapy.  
Outcomes 
Follow-up is insufficient to evaluate OS and long-term safety. Mature OS data and QoL measures are 
needed to ensure patients achieve a clinically relevant benefit over time despite manageable toxicity.  
Setting 
iNNOVATE is a multinational, study conducted in 45 sites across Australia, Canada, France, Germany, 
Greece, Italy, Spain, United Kingdom, and the United States.  
Abbreviations: BICR = blinded independent central review; BTK = Bruton tyrosine kinase; CI = confidence interval; CNS = central nervous 
system; CR = complete response; CRR = clinical response rate; CVD = cardiovascular disease; DOR = duration of response; ECOG = Eastern 
Cooperative Oncology Group; FACT-An = Functional Assessment of Cancer Therapy-Anaemia; Hb = haemoglobin; HR = hazard ratio; IgM = 
immunoglobulin M; IPSSWM = International Prognostic Scoring System for Waldenström’s Macroglobulinemia; IV = intravenous; IWWM = 
International Workshop on Waldenström’s Macroglobulinemia; MR = minor response; MRU = medical resource utilization; NCCN = National 
Comprehensive Cancer Network; NR = not reported; ORR = overall response rate;  PFS = progression-free survival; PR = partial response; 
QoL = quality of life; RCT = randomised controlled trial; TTNT = time to next treatment; WM = Waldenström’s Macroglobulinemia; WT = 
wild type 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [32] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomised 1:1 to ibrutinib + rituximab or 
placebo + rituximab using the IWRS system.  Randomisation was stratified according to the 
WM IPSS score assessed at screening (low versus intermediate versus high), prior systemic 
treatment regimens (0 versus 1-2 versus >3), and ECOG performance status score (0 or 1 ver-
sus 2). 
yes 
Adequate allocation concealment: centralised randomisation and allocation; blinded study 
medication was administered based on assignment from the IWRS 
yes 
Blinding: 
Patient: centralised randomisation and allocation; received ibrutinib or 
matching placebo on an outpatient basis 
yes 
Treating physician: centralised randomisation and allocation; patients re-
ceived ibrutinib or matching placebo on an outpatient basis 
yes 
Outcome assessor: centralised randomisation and allocation; BICR-
assessed efficacy and safety at pre-specified interim analysis; sensitivity 
analysis was planned to assess PFS and ORR by predefined subgroups. Re-
sponse defined based on modified Consensus Response Criteria from VIth 
International Workshop for WM, NCCN. 
yes 
Selective outcome reporting unlikely: primary endpoint of PFS, secondary endpoints of OS, 
ORR, Hb, TTNT, and AEs, and exploratory endpoints of investigator assessed PFS and ORR, 
DOR, CRR were reported. Other endpoints not included in this analysis are QoL and medical 
resource utilization, as per protocol.  
yes 
No other aspects which increase the risk of bias: industry funded the study, collected data, 
confirmed data for accuracy, compiled the data for analysis, performed statistical analysis, 
drafted and reviewed the manuscript.  
no 
Risk of bias – study level low-risk 
Abbreviations: ECOG = Eastern Cooperative Oncology Group; IPSSWM = International Prognostic Scoring System for Waldenström’s 
Macroglobulinemia; IVRS/IWRS = interactive web response system; NCCN = National Cancer Care Network, WM = Waldenström’s 
macroglobulinemia 
 
 
 
 
